These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8105790)

  • 1. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic role of naltrexone in negative symptom schizophrenia.
    Marchesi GF; Santone G; Cotani P; Giordano A; Chelli F
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1239-49. PubMed ID: 8868206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone augmentation of neuroleptics in schizophrenia.
    Sernyak MJ; Glazer WM; Heninger GR; Charney DS; Woods SW; Petrakis IL; Krystal JH; Price LH
    J Clin Psychopharmacol; 1998 Jun; 18(3):248-51. PubMed ID: 9617985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotogenic drug use and neuroleptic response.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Schizophr Bull; 1990; 16(1):81-5. PubMed ID: 1970670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naltrexone on mannerisms and water imbalance in polydipsic schizophrenics: a pilot study.
    Becker JA; Goldman MB; Alam MY; Luchins DJ
    Schizophr Res; 1995 Nov; 17(3):279-82. PubMed ID: 8664207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
    Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
    Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
    Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J
    Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate augmentation therapy in schizophrenia.
    Carpenter MD; Winsberg BG; Camus LA
    J Clin Psychopharmacol; 1992 Aug; 12(4):273-5. PubMed ID: 1527231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive.
    Glick ID; Bosch J; Casey DE
    J Clin Psychopharmacol; 2009 Jun; 29(3):267-71. PubMed ID: 19440081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.